Evidence-based follow-up for the patient with melanoma

Surgical Oncology Clinics of North America

Volumn 20, Issue 1, 2011, Pages 181-200

  Fields, Ryan C ^a   Coit, Daniel G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Evidence based follow up; Melanoma; Outcomes

Indexed keywords

LACTATE DEHYDROGENASE; MELANOMA INHIBITORY ACTIVITY PROTEIN; ONCOPROTEIN; PROTEIN S100B; UNCLASSIFIED DRUG;

BONE METASTASIS; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; EVIDENCE BASED MEDICINE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOLLOW UP; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT EDUCATION; PATIENT SATISFACTION; PRACTICE GUIDELINE; PROTEIN DETERMINATION; REVIEW; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY;

DECISION MAKING; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; INCIDENCE; LUNG NEOPLASMS; LYMPH NODES; MELANOMA; NEOPLASM RECURRENCE, LOCAL; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; PROGNOSIS; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 78649479827     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2010.09.009     Document Type: Review

References (71)

1. Francken A.B., Bastiaannet E., Hoekstra H.J. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005, 6(8):608-621.
2. Nieweg O.E., Kroon B.B. The conundrum of follow-up: should it be abandoned?. Surg Oncol Clin N Am 2006, 15(2):319-330.
3. Wong J.H., Skinner K.A., Kim K.A., et al. The role of surgery in the treatment of nonregionally recurrent melanoma. Surgery 1993, 113(4):389-394.
4. Soong S.J., Ding S., Coit D., et al. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC melanoma database. Ann Surg Oncol 2010, 17(8):2006-2014.
5. Eigentler T.K., Caroli U.M., Radny P., et al. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003, 4(12):748-759.
6. Weiss M., Loprinzi C.L., Creagan E.T., et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995, 274(21):1703-1705.
7. Francken A.B., Hoekstra H.J. Follow-up of melanoma patients: the need for evidence-based protocols. Ann Surg Oncol 2009, 16(4):804-805.
8. Garbe C., Paul A., Kohler-Spath H., et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003, 21(3):520-529.
9. McCarthy W.H., Shaw H.M., Thompson J.F., et al. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988, 166(6):497-502.
10. Martini L., Brandani P., Chiarugi C., et al. First recurrence analysis of 840 cutaneous melanomas: a proposal for a follow-up schedule. Tumori 1994, 80(3):188-197.
11. Dicker T.J., Kavanagh G.M., Herd R.M., et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol 1999, 140(2):249-254.
12. Rosenkranz L., Schroeder C. Recurrent malignant melanoma following a 46-year disease-free interval. N Y State J Med 1985, 85(3):95.
13. Francken A.B., Accortt N.A., Shaw H.M., et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg 2008, 95(11):1401-1407.
14. Baughan C.A., Hall V.L., Leppard B.J., et al. Follow-up in stage I cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol) 1993, 5(3):174-180.
15. Hofmann U., Szedlak M., Rittgen W., et al. Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002, 87(2):151-157.
16. Francken A.B., Shaw H.M., Accortt N.A., et al. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 2007, 14(6):1924-1933.
17. Francken A.B., Thompson J.F., Bastiaannet E., et al. Ned Tijdschr Geneeskd 2008, 152(10):557-562. [in Dutch].
18. Einwachter-Thompson J., MacKie R.M. An evidence base for reconsidering current follow-up guidelines for patients with cutaneous melanoma less than 0.5 mm thick at diagnosis. Br J Dermatol 2008, 159(2):337-341.
19. Meyers M.O., Yeh J.J., Frank J., et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol 2009, 16(4):941-947.
20. Mooney M.M., Kulas M., McKinley B., et al. Impact on survival by method of recurrence detection in stage I and II cutaneous melanoma. Ann Surg Oncol 1998, 5(1):54-63.
21. Poo-Hwu W.J., Ariyan S., Lamb L., et al. Follow-up recommendations for patients with American Joint Committee on cancer stages I-III malignant melanoma. Cancer 1999, 86(11):2252-2258.
22. Romano E., Scordo M., Dusza S.W., et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 2010, 28(18):3042-3047.
23. NCCN Clinical Practice Guidelines in Oncology: Melanoma Available at:, Accessed July 26, 2010. http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf.
24. Dummer R., Bosch U., Panizzon R., et al. Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2001, 203(1):75-80.
25. Dummer R., Hauschild A., Guggenheim M., et al. Melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v194-v197.
26. Garbe C., Hauschild A., Volkenandt M., et al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 2007, 17(6):393-399.
27. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand Available at:, Accessed July 26, 2010. http://www.nhmrc.gov.au/_files_nhmrc/file/publications/synopses/cp111.pdf.
28. Murchie P., Nicolson M.C., Hannaford P.C., et al. Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial. Br J Cancer 2010, 102(10):1447-1455.
29. Provost N., Marghoob A.A., Kopf A.W., et al. Laboratory tests and imaging studies in patients with cutaneous malignant melanomas: a survey of experienced physicians. J Am Acad Dermatol 1997, 36(5 Pt 1):711-720.
30. Huang C.L., Provost N., Marghoob A.A., et al. Laboratory tests and imaging studies in patients with cutaneous malignant melanoma. J Am Acad Dermatol 1998, 39(3):451-463.
31. Kersey P.A., Iscoe N.A., Gapski J.A., et al. The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma. Br J Surg 1985, 72(8):614-617.
32. Campora E., Repetto L., Giuntini P., et al. LDH in the follow-up of stage I malignant melanoma. Eur J Cancer Clin Oncol 1988, 24(2):277-278.
33. Balch C.M., Soong S.J., Atkins M.B., et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004, 54(3):131-149. [quiz: 182-4].
34. Cochran A.J., Wen D.R., Herschman H.R., et al. Detection of S-100 protein as an aid to the identification of melanocytic tumors. Int J Cancer 1982, 30(3):295-297.
35. Bonfrer J.M., Korse C.M., Nieweg O.E., et al. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer 1998, 77(12):2210-2214.
36. Guo H.B., Stoffel-Wagner B., Bierwirth T., et al. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer Am 1995, 31(11):1898-1902.
37. Jury C.S., McAllister E.J., MacKie R.M. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 2000, 143(2):269-274.
38. Garbe C., Leiter U., Ellwanger U., et al. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 2003, 97(7):1737-1745.
39. Harpole D.H., Johnson C.M., Wolfe W.G., et al. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 1992, 103(4):743-748. [discussion: 748-50].
40. Coit D.G. Role of surgery for metastatic malignant melanoma: a review. Semin Surg Oncol 1993, 9(3):239-245.
41. Allen P.J., Coit D.G. The role of surgery for patients with metastatic melanoma. Curr Opin Oncol 2002, 14(2):221-226.
42. Wong J.H., Euhus D.M., Morton D.L. Surgical resection for metastatic melanoma to the lung. Arch Surg 1988, 123(9):1091-1095.
43. Bassères N., Grob J.J., Richard M.A., et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 1995, 191(3):199-203.
44. Goerz G., Schulte-Beerbuhl R., Roder K., et al. Dtsch Med Wochenschr 1986, 111(33):1230-1233. [in German].
45. Bastien M., Tessier M.H., Legoux B., et al. Usefulness of paraclinical follow-up in stage I melanoma. Arch Dermatol 1997, 133(11):1462-1463.
46. Kittler H., Weitzdorfer R., Pehamberger H., et al. Compliance with follow-up and prognosis among patients with thin melanomas. Eur J Cancer 2001, 37(12):1504-1509.
47. Mijnhout G.S., Teule G.J., Hoekstra O.S., et al. Ned Tijdschr Geneeskd 1999, 143(19):997-1001. [in Dutch].
48. Mooney M.M., Mettlin C., Michalek A.M., et al. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer 1997, 80(6):1052-1064.
49. Tsao H., Feldman M., Fullerton J.E., et al. Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. Arch Dermatol 2004, 140(1):67-70.
50. Morton R.L., Craig J.C., Thompson J.F. The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol 2009, 16(3):571-577.
51. Toyoda Y., Nakayama T., Kusunoki Y., et al. Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography. Br J Cancer 2008, 98(10):1602-1607.
52. Tregnaghi A., De Candia A., Calderone M., et al. Ultrasonographic evaluation of superficial lymph node metastases in melanoma. Eur J Radiol 1997, 24(3):216-221.
53. Binder M., Kittler H., Steiner A., et al. Lymph node sonography versus palpation for detecting recurrent disease in patients with malignant melanoma. Eur J Cancer 1997, 33(11):1805-1808.
54. Blum A., Schlagenhauff B., Stroebel W., et al. Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow-up of patients with cutaneous melanoma: results of a prospective study of 1288 patients. Cancer 2000, 88(11):2534-2539.
55. Voit C., Mayer T., Kron M., et al. Efficacy of ultrasound B-scan compared with physical examination in follow-up of melanoma patients. Cancer 2001, 91(12):2409-2416.
56. Brountzos E.N., Panagiotou I.E., Bafaloukos D.I., et al. Ultrasonographic detection of regional lymph node metastases in patients with intermediate or thick malignant melanoma. Oncol Rep 2003, 10(2):505-510.
57. Bafounta M.L., Beauchet A., Chagnon S., et al. Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. Lancet Oncol 2004, 5(11):673-680.
58. Machet L., Perrinaud A., Giraudeau B. Routine ultrasonography in melanoma follow-up?. Lancet Oncol 2005, 6(1):2. [discussion: 3].
59. Complete lymph node dissection or observation in treating patients with localized melanoma and sentinel node metastasis who have undergone sentinel lymphadenectomy Available at:, Accessed August 6, 2010. http://clinicaltrials.gov/ct2/show/NCT00389571%3Fterm%3Dmslt%26rank%3D8.
60. Rose D.M., Essner R., Hughes T.M., et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg 2001, 136(8):950-955.
61. Berger A.C., Buell J.F., Venzon D., et al. Management of symptomatic malignant melanoma of the gastrointestinal tract. Ann Surg Oncol 1999, 6(2):155-160.
62. Saha S., Meyer M., Krementz E.T., et al. Prognostic evaluation of intracranial metastasis in malignant melanoma. Ann Surg Oncol 1994, 1(1):38-44.
63. Ferrone C.R., Ben Porat L., Panageas K.S., et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005, 294(13):1647-1654.
64. Roberts D.L., Anstey A.V., Barlow R.J., et al. U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 2002, 146(1):7-17.
65. Goggins W.B., Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003, 97(3):639-643.
66. Johnson T.M., Hamilton T., Lowe L. Multiple primary melanomas. J Am Acad Dermatol 1998, 39(3):422-427.
67. Longman A.J., Graham K.Y. Living with melanoma: content analysis of interviews. Oncol Nurs Forum 1986, 13(4):58-64.
68. Brandberg Y., Mansson-Brahme E., Ringborg U., et al. Psychological reactions in patients with malignant melanoma. Eur J Cancer 1995, 31A(2):157-162.
69. Schofield P.E., Butow P.N., Thompson J.F., et al. Psychological responses of patients receiving a diagnosis of cancer. Ann Oncol 2003, 14(1):48-56.
70. Dancey A., Rayatt S., Courthold J., et al. Views of UK melanoma patients on routine follow-up care. Br J Plast Surg 2005, 58(2):245-250.
71. Fawzy F.I., Canada A.L., Fawzy N.W. Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. Arch Gen Psychiatry 2003, 60(1):100-103.